Publications and Presentations

AI Advances Healthcare Research

AI Advances Healthcare Research

AI advances healthcare research – an interview with Matt Segall in Scientific Computing World, 2018.


Harnessing AI for drug discovery applications will significantly speed the identification of promising drug candidates, believes Matt Segall, CEO at Optibrium. The UK-based firm, together with partners Intellegens and Medicines Discovery Catapult, recently received a grant from Innovate UK to help fund a £1 million project focussed on combining Optibrium’s existing StarDrop software for small molecule design, optimisation and data analysis, and Intellegen’s deep learning platform Alchemite.

The aim is to develop a novel, deep learning AI-based method for predicting the ADMET (absorbtion, distribution, metabolism, excretion and toxicity) properties of new drugs candidates. Ultimately, the platform could help to guide the selection and design of more effective, safer compounds earlier in the discovery process…

Find out more

Visit the Scientific Computing World page to read this article ‘AI Advances Healthcare Research’.


Discover Cerella™

Cerella™ is a unique artificial intelligence platform which supports medicinal chemists and other discovery scientists. It escalates success rates and advances small molecule drug discovery, from working with early hits to nominating preclinical candidates. 

Cerella’s AI platform is proven to overcome limitations in drug discovery data, confidently delivering results and seamlessly integrating with your med chem software platforms.